Latest News for: sarepta
Edit
Notice of Proposed Sale of Securities (Form 144) (Sarepta Therapeutics Inc)
Public Technologies 16 Dec 2025
Edit
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 (Form 8-K) (Sarepta Therapeutics Inc)
Public Technologies 11 Dec 2025
). Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027. CAMBRIDGE, Mass., December 11, 2025 (BUSINESS WIRE) - Sarepta Therapeutics, Inc ... Disclaimer. Sarepta Therapeutics Inc ... (noodl.
Edit
The Galveston Daily News
11 Dec 2025
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
Edit
Statement of Changes in Beneficial Ownership (Form 4) (Sarepta Therapeutics Inc)
Public Technologies 11 Dec 2025
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... 0.5 ... 2 ... Sarepta Therapeutics, Inc ... 6 ... Sarepta Therapeutics Inc.
Edit
Management Change/Compensation (Form 8-K) (Sarepta Therapeutics Inc)
Public Technologies 08 Dec 2025
) Item 5.02 ... On December 7, 2025, the Board of Directors (the "Board") of Sarepta Therapeutics, Inc. (the "Company") granted equity awards to Douglas S ... Attachments Original document Permalink. Disclaimer. Sarepta Therapeutics Inc.
Edit
The Galveston Daily News
25 Nov 2025
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part ...
Edit
The Milton Standard Journal
24 Nov 2025
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
Edit
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Business Wire 24 Nov 2025
Edit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
PR Newswire 20 Nov 2025
Edit
TOWNS: Hochul Can Lead the Nation in Gene Therapy Access for Our Children
The Washington Informer 20 Nov 2025
Kathy Hochul has demonstrated a commitment to accessible health care and drug innovation in New York, but the state's Drug ...
Edit
The Huntsville Item
15 Nov 2025
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
Edit
Ottumwa Courier
15 Nov 2025
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year. Sarepta Therapeutics' Elevidys will carry the FDA's strongest warning label about the risks of liver damage and liver ... .
Edit
Scottsbluff StarHerald
15 Nov 2025
FDA adds strongest warning to Sarepta gene therapy
WASHINGTON — The Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne's muscular dystrophy that's been linked to two patient deaths ... .
Edit
Quarterly Report for Quarter Ending September 30, 2025 (Form 10-Q) (Sarepta Therapeutics Inc)
Public Technologies 06 Nov 2025- 1
- 2
- Next page »